27 Oct 2016 07:15
Hardman Research: Get the Rhythm
Get the rhythm: Diurnal is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. It has two lead candidates - Infacort® and Chronocort® - in Phase III trials targeted at rare diseases with unmet medical need with which it aims to build a long-term 'Adrenal Franchise'. The cortisol replacement market is for conditions that need life-long treatments, with a potential value of $3.5bn. Despite this, the market is characterised by few competitors, and Diurnal will target a network of specialist endocrinology centres in Europe and US by itself. Upcoming newsflow on trials and regulatory filings will draw attention to the stock.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/diurnal-ltd-documents/27.10.16-get-the-rhythm.pdf
To contact us: Hardman & Co 11/12 Tokenhouse Yard London EC2R 7AS | Contact: Dr Martin Hall mh@hardmanandco.com Dr Dorothea Hill dmh@hardmanandco.com Dr Gregoire Pave gp@hardmanabdco.com Telephone: +44 20 7929 3399 Follow us on Twitter @HardmanandCo
|
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
DNL.L (DNL)